Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Mizuta

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Anticancer Research|January 30, 2026
Glutamine Dependence Is Not a Cancer-specific Vulnerability in Contrast to Methionine DependenceYuta Miyashi, Kohei Mizuta, Yohei Asano, et al.
Cancer Genomics & Proteomics|February 24, 2025
Engineered Methioninase-expressing Tumor-targeting <i>Salmonella typhimurium</i> A1-R Inhibits Syngeneic-Cancer Mouse Models by Depleting Tumor MethionineYutaro Kubota, Ming Zhao, Qinghong Han, et al.
Anticancer Research|December 30, 2023
Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon CancerMotokazu Sato, Qinghong Han, Yutaro Kubota, et al.
Cancer Diagnosis & Prognosis|January 6, 2025
Prostate Cancer Patient With Lymph-node Metastasis Treated Only With Methionine Restriction Has Stable Disease for Two Years Demonstrated With PET/CT and PSMA-PET Scanning and PSA TestingSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Cancer Diagnosis & Prognosis|January 6, 2025
Complete Response (CR) in a Previously-progressing Chronic Lymphocytic Leukemia (CLL) Patient Treated With Methionine Restriction in Combination With First-line ChemotherapySei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|December 31, 2024
The Combination of Tumor-targeting <i>Salmonella typhimurium</i> A1-R Plus the Autophagy-inhibitor Chloroquine Synergistically Eradicates HT1080 Fibrosarcoma Cells <i>In Vitro</i> and <i>In Vivo</i>Sei Morinaga, Ming Zhao, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|February 26, 2025
HT1080 Fibrosarcoma With Acquired Trabectedin Resistance: Increased Malignancy But Sustained Sensitivity to Methionine RestrictionSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|March 4, 2025
Highly Synergistic Eradication of 143B Osteosarcoma Cells <i>In Vitro</i> by the Combination of Recombinant Methioninase, Chloroquine, and Rapamycin Targeting Methionine Addiction, Autophagy, and mTOR, RespectivelySei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|December 31, 2024
Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer CellsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|April 28, 2025
HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance <i>In Vitro</i> Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude MiceSei Morinaga, Kohei Mizuta, Byung Mo Kang, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Anticancer Research|January 30, 2026
Glutamine Dependence Is Not a Cancer-specific Vulnerability in Contrast to Methionine DependenceYuta Miyashi, Kohei Mizuta, Yohei Asano, et al.
Cancer Genomics & Proteomics|February 24, 2025
Engineered Methioninase-expressing Tumor-targeting <i>Salmonella typhimurium</i> A1-R Inhibits Syngeneic-Cancer Mouse Models by Depleting Tumor MethionineYutaro Kubota, Ming Zhao, Qinghong Han, et al.
Anticancer Research|December 30, 2023
Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon CancerMotokazu Sato, Qinghong Han, Yutaro Kubota, et al.
Cancer Diagnosis & Prognosis|January 6, 2025
Prostate Cancer Patient With Lymph-node Metastasis Treated Only With Methionine Restriction Has Stable Disease for Two Years Demonstrated With PET/CT and PSMA-PET Scanning and PSA TestingSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Cancer Diagnosis & Prognosis|January 6, 2025
Complete Response (CR) in a Previously-progressing Chronic Lymphocytic Leukemia (CLL) Patient Treated With Methionine Restriction in Combination With First-line ChemotherapySei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|December 31, 2024
The Combination of Tumor-targeting <i>Salmonella typhimurium</i> A1-R Plus the Autophagy-inhibitor Chloroquine Synergistically Eradicates HT1080 Fibrosarcoma Cells <i>In Vitro</i> and <i>In Vivo</i>Sei Morinaga, Ming Zhao, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|February 26, 2025
HT1080 Fibrosarcoma With Acquired Trabectedin Resistance: Increased Malignancy But Sustained Sensitivity to Methionine RestrictionSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|March 4, 2025
Highly Synergistic Eradication of 143B Osteosarcoma Cells <i>In Vitro</i> by the Combination of Recombinant Methioninase, Chloroquine, and Rapamycin Targeting Methionine Addiction, Autophagy, and mTOR, RespectivelySei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|December 31, 2024
Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer CellsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|April 28, 2025
HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance <i>In Vitro</i> Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude MiceSei Morinaga, Kohei Mizuta, Byung Mo Kang, et al.
Pageof 8